Karyopharm Therapeutics (KPTI) Stock: Buy, Sell, or Hold?
KPTI - Karyopharm Therapeutics Inc.
$1.61
-0.01 (-0.62%)
▼
5d:
-9.04%
30d:
-20.69%
90d:
-82.11%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 02, 2026
Get Alerted When KPTI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: KPTI shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: KPTI shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: KPTI is currently trading at $1.61, which is considered oversold relative to its 30-day fair value range of $1.77 to $2.03.
Technical Outlook: Technically, KPTI is in a strong downtrend. Immediate support is located at $1.24, while resistance sits at $2.14.
Market Sentiment: KPTI scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.25 (+350.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, KPTI is in a strong downtrend. Immediate support is located at $1.24, while resistance sits at $2.14.
Market Sentiment: KPTI scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.25 (+350.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.77 -
$2.03
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 350.3% below Wall St target ($7.25)
- WARNING: Composite score 41/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.77 -
$2.03
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.24
Resistance Level
$2.14
Current Trend
Strong Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.57
Wall Street Target
$7.25
(+350.3%)
Revenue Growth (YoY)
-11.9%
Profit Margin
-153.3%
Share & Embed Analysis
Last updated: September 13, 2026 4:29 AM ET
Data refreshes hourly during market hours. Next update: 5:29 AM
Data refreshes hourly during market hours. Next update: 5:29 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KPTI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Reshma Rangwala
SELL
449 shares
2026-04-21
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 58 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 45 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 60 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 57 HOLD |
